These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9099167)

  • 61. Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.
    Gumbs PD; Verschuren MW; Mantel-Teeuwisse AK; de Wit AG; de Boer A; Klungel OH
    Pharmacoeconomics; 2007; 25(3):187-99. PubMed ID: 17335305
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effectiveness calculation in economic analysis: the case of statins for cardiovascular disease prevention.
    Franco OH; Steyerberg EW; Peeters A; Bonneux L
    J Epidemiol Community Health; 2006 Oct; 60(10):839-45. PubMed ID: 16973528
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.
    Kohli M; Attard C; Lam A; Huse D; Cook J; Bourgault C; Alemao E; Yin D; Marentette M
    Pharmacoeconomics; 2006; 24(8):815-30. PubMed ID: 16898850
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost effectiveness of statins in coronary heart disease.
    Franco OH; Peeters A; Looman CW; Bonneux L
    J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacoeconomic impact of non-compliance with statins.
    Peterson AM; McGhan WF
    Pharmacoeconomics; 2005; 23(1):13-25. PubMed ID: 15693725
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost of managing complications resulting from type 2 diabetes mellitus in Canada.
    O'Brien JA; Patrick AR; Caro JJ
    BMC Health Serv Res; 2003 Mar; 3(1):7. PubMed ID: 12659641
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada.
    Coyle D; Palmer AJ; Tam R
    Pharmacoeconomics; 2002; 20 Suppl 1():31-42. PubMed ID: 12036382
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
    Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
    Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
    CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
    Goa KL; Barradell LB; McTavish D
    Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Difficulties and limits in the evaluation of the cost of coronary disease in France].
    Clémenty J; Delpech MC; Mazeau C; Stingre P; Bricaud H
    Arch Mal Coeur Vaiss; 1983 Feb; 76 Spec No():55-67. PubMed ID: 6407450
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.